Do analysts prefer APM or ASLN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptorum Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, APM or ASLN?

Aptorum Group has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptorum Group N/A N/A -$1.36M N/A N/A ASLAN Pharmaceuticals $12M 0.10 -$44.22M -$21.92 N/A

Is APM or ASLN more profitable?

Aptorum Group's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aptorum Group N/A N/A N/A ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

Do analysts recommend ASLN or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASLN or BGMS more profitable?

Cyclacel Pharmaceuticals' return on equity of -51.21% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts rate ASLN or FBLG?

FibroBiologics has a consensus target price of $74.00, indicating a potential upside of 8,680.26%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than ASLAN Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 FibroBiologics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ASLN or FBLG more profitable?

FibroBiologics' return on equity of -767.07% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% FibroBiologics N/A -767.07% -195.56%

Do analysts rate ASLN or ALZN?

Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 2,176.42%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than ASLAN Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ASLN or ALZN more profitable?

Alzamend Neuro's return on equity of -177.52% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Alzamend Neuro N/A -177.52% -140.41%

ASLAN Pharmaceuticals (ASLN) Competitors

$0.60 0.00 (0.00%)

As of 07/14/2026

Compare

ASLN vs. APM, BGMS, FBLG, ALZN, and SXTP

Should you buy ASLAN Pharmaceuticals stock or one of its competitors? MarketBeat compares ASLAN Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ASLAN Pharmaceuticals include Aptorum Group (APM), Cyclacel Pharmaceuticals (BGMS), FibroBiologics (FBLG), Alzamend Neuro (ALZN), and 60 Degrees Pharmaceuticals (SXTP). These companies are all part of the "pharmaceutical products" industry.

How does ASLAN Pharmaceuticals compare to Aptorum Group?

Aptorum Group (NASDAQ:APM) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Aptorum Group has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

In the previous week, Aptorum Group had 2 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 2 mentions for Aptorum Group and 0 mentions for ASLAN Pharmaceuticals. Aptorum Group's average media sentiment score of 0.72 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Aptorum Group is being referred to more favorably in the media.

Company	Overall Sentiment
Aptorum Group	Positive
ASLAN Pharmaceuticals	Neutral

3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 64.0% of Aptorum Group shares are held by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aptorum Group has higher earnings, but lower revenue than ASLAN Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	N/A	N/A	-$1.36M	N/A	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

Aptorum Group's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Aptorum Group beats ASLAN Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Cyclacel Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Cyclacel Pharmaceuticals' return on equity of -51.21% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

In the previous week, Cyclacel Pharmaceuticals had 2 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 2 mentions for Cyclacel Pharmaceuticals and 0 mentions for ASLAN Pharmaceuticals. Cyclacel Pharmaceuticals' average media sentiment score of 1.44 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Cyclacel Pharmaceuticals	Positive

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Cyclacel Pharmaceuticals	$750K	6.66	-$3M	-$4.54	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.38, indicating that its share price is 138% less volatile than the broader market.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Cyclacel Pharmaceuticals beats ASLAN Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to FibroBiologics?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

FibroBiologics has a consensus target price of $74.00, indicating a potential upside of 8,680.26%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

FibroBiologics has lower revenue, but higher earnings than ASLAN Pharmaceuticals. FibroBiologics is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

In the previous week, FibroBiologics had 3 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 3 mentions for FibroBiologics and 0 mentions for ASLAN Pharmaceuticals. FibroBiologics' average media sentiment score of 0.88 beat ASLAN Pharmaceuticals' score of 0.00 indicating that FibroBiologics is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
FibroBiologics	Positive

FibroBiologics' return on equity of -767.07% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
FibroBiologics	N/A	-767.07%	-195.56%

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

FibroBiologics beats ASLAN Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Alzamend Neuro?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

Alzamend Neuro's return on equity of -177.52% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Alzamend Neuro	N/A	-177.52%	-140.41%

Alzamend Neuro has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Alzamend Neuro is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

In the previous week, Alzamend Neuro had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Alzamend Neuro and 0 mentions for ASLAN Pharmaceuticals. Alzamend Neuro's average media sentiment score of 1.87 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Alzamend Neuro	Very Positive

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.14, indicating that its share price is 86% less volatile than the broader market.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 2,176.42%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Alzamend Neuro beats ASLAN Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

60 Degrees Pharmaceuticals has higher earnings, but lower revenue than ASLAN Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.92	-$7.36M	-$8.92	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for ASLAN Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.62 beat ASLAN Pharmaceuticals' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Positive
ASLAN Pharmaceuticals	Neutral

60 Degrees Pharmaceuticals currently has a consensus target price of $13.85, suggesting a potential upside of 793.55%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

60 Degrees Pharmaceuticals has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

ASLAN Pharmaceuticals has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

60 Degrees Pharmaceuticals beats ASLAN Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get ASLAN Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASLN vs. The Competition

Export

Metric	ASLAN Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.23M	$940.63M	$6.78B	$12.56B
Dividend Yield	N/A	4.84%	2.68%	9.46%
P/E Ratio	-0.03	1.56	27.12	24.35
Price / Sales	0.10	114.57	487.66	77.47
Price / Cash	N/A	20.06	48.63	60.00
Price / Book	-0.09	8.58	10.82	6.31
Net Income	-$44.22M	-$3.40M	$3.59B	$331.55M
7 Day Performance	N/A	-2.12%	-1.21%	0.15%
1 Month Performance	N/A	-1.06%	3.13%	-0.68%
1 Year Performance	N/A	35.43%	29.12%	20.73%

ASLAN Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASLN ASLAN Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$1.23M	$12M	N/A	30
APM Aptorum Group	0.9677 of 5 stars	$0.78 +1.2%	N/A	-14.5%	$4.89M	$430K	N/A	30	Short Interest Decrease
BGMS Cyclacel Pharmaceuticals	1.4231 of 5 stars	$0.87 -1.5%	N/A	N/A	$4.88M	$750K	N/A	14	Analyst Downgrade Short Interest Decrease
FBLG FibroBiologics	2.6123 of 5 stars	$0.82 -2.8%	$74.00 +8,959.7%	-93.3%	$4.38M	N/A	N/A	10	Gap Down
ALZN Alzamend Neuro	2.7806 of 5 stars	$1.15 +0.9%	$28.00 +2,334.8%	-61.7%	$4.34M	N/A	N/A	4	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASLN) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. APM, BGMS, FBLG, ALZN, and SXTP

How does ASLAN Pharmaceuticals compare to Aptorum Group?

Summary

How does ASLAN Pharmaceuticals compare to Cyclacel Pharmaceuticals?

Summary

How does ASLAN Pharmaceuticals compare to FibroBiologics?

Summary

How does ASLAN Pharmaceuticals compare to Alzamend Neuro?

Summary

How does ASLAN Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. APM, BGMS, FBLG, ALZN, and SXTP

How does ASLAN Pharmaceuticals compare to Aptorum Group?

Which has more volatility and risk, APM or ASLN?

Does the media refer more to APM or ASLN?

Do institutionals and insiders believe in APM or ASLN?

Which has higher earnings and valuation, APM or ASLN?

Is APM or ASLN more profitable?

Do analysts prefer APM or ASLN?

Summary

How does ASLAN Pharmaceuticals compare to Cyclacel Pharmaceuticals?

Is ASLN or BGMS more profitable?

Does the media refer more to ASLN or BGMS?

Which has stronger earnings and valuation, ASLN or BGMS?

Do analysts recommend ASLN or BGMS?

Which has more risk & volatility, ASLN or BGMS?

Do institutionals and insiders believe in ASLN or BGMS?

Summary

How does ASLAN Pharmaceuticals compare to FibroBiologics?

Which has more volatility & risk, ASLN or FBLG?

Do analysts rate ASLN or FBLG?

Which has preferable valuation & earnings, ASLN or FBLG?

Does the media favor ASLN or FBLG?

Is ASLN or FBLG more profitable?

Do institutionals & insiders hold more shares of ASLN or FBLG?

Summary

How does ASLAN Pharmaceuticals compare to Alzamend Neuro?

Is ASLN or ALZN more profitable?

Which has better valuation and earnings, ASLN or ALZN?

Does the media favor ASLN or ALZN?

Which has more risk and volatility, ASLN or ALZN?

Do insiders & institutionals hold more shares of ASLN or ALZN?

Do analysts rate ASLN or ALZN?

Summary

How does ASLAN Pharmaceuticals compare to 60 Degrees Pharmaceuticals?

Which has preferable valuation and earnings, SXTP or ASLN?

Does the media prefer SXTP or ASLN?

Do analysts recommend SXTP or ASLN?

Which has more risk and volatility, SXTP or ASLN?

Is SXTP or ASLN more profitable?

Do institutionals and insiders have more ownership in SXTP or ASLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools